Table 3.

TEAE frequency in PCSK9 mAbs clinical trials in HeFH patients

TEAEs	PCSK9 mAbs	Placebo
TEAEs (any)	51%–81.7%	28%–82.5%
Serious adverse events	1.8%–18.7%	0%–19.5%
Leading to death	0%–1.9%	0%–1.3%
Leading to treatment discontinuation	0%–7.2%	0%–6.1%
Common adverse events
Injection site reaction	2.4%–12.4%	0%–11%
Nasopharyngitis	7%–13.9%	4%–22.2%
Influenza	4.5%–14.4%	2.9%–10.7%
Headache	4%–9.6%	0%–8.9%
Diarrhea	1.8%–9.8%	0%–8.6%
Nausea	1.8%–4.9%	0%–14.3%
Myalgia	1.9%–9.8%	0%–8.6%

Abbreviations: HeFH, heterozygous familial hypercholesterolemia; mAb, monoclonal antibody; PCSK9, proprotein convertase subtilisin kexin 9; TEAEs, treatment-emergent adverse events.